Calcium Signalling and EBC-46: ER Stress and Intracellular Calcium in Tumour Cell Death

Among the intracellular events that follow tigilanol tiglate (EBC-46) exposure in tumour cells, disturbance of calcium homeostasis has emerged as one of the more consistent findings in published mechanistic work. Calcium acts as a second messenger across most cellular processes, and a sustained loss of calcium control in a tumour cell triggers endoplasmic reticulum (ER) stress, mitochondrial dysfunction, and programmed cell death pathways. This article summarises what the peer-reviewed literature reports about calcium signalling in the EBC-46 mechanism — without making any health or therapeutic claims for dietary supplements.

Calcium as a second messenger

In a healthy cell, cytosolic calcium sits at roughly 100 nanomolar, while the endoplasmic reticulum stores calcium at millimolar concentrations. Tightly regulated release through IP3 receptors and ryanodine receptors allows calcium to function as a rapid messenger controlling enzyme activation, gene transcription, and membrane-trafficking events. When calcium release becomes uncontrolled or prolonged, the cell shifts into a stress-response state.

PKC-delta activation and downstream calcium flux

Tigilanol tiglate is characterised in the primary literature as an activator of protein kinase C isoforms, particularly PKC-delta. Published mechanistic studies describe how PKC-delta activation propagates a signal that results in calcium release from intracellular stores. This is the upstream step — it is what sets off the downstream cascade rather than being a direct membrane-perforating event.

Endoplasmic reticulum stress response

Sustained calcium depletion from the ER lumen triggers the unfolded protein response (UPR). Three ER membrane sensors — PERK, IRE1α, and ATF6 — detect the loss of calcium-dependent chaperone activity and initiate a coordinated transcriptional programme. If ER homeostasis is not restored, the UPR transitions from a pro-survival to a pro-apoptotic signalling mode. Published work on tigilanol tiglate-exposed cells reports hallmarks consistent with this transition.

Mitochondrial permeability transition

Calcium released from the ER is taken up by neighbouring mitochondria through the mitochondrial calcium uniporter. Mitochondrial calcium overload opens the permeability transition pore, depolarising the inner membrane and releasing cytochrome c into the cytosol. Cytochrome c release activates caspase-9 and the intrinsic apoptotic pathway. This ER-to-mitochondria calcium transfer is a well-characterised apoptotic trigger across many stress contexts and appears to be part of the tigilanol tiglate cascade as well.

Why selectivity matters here

One reason this mechanism is of research interest is selectivity: tumour cells characteristically operate closer to their calcium-handling limit than healthy cells. A stressor that pushes calcium flux past the threshold can produce disproportionate effects in transformed cells while leaving normal tissue more resilient. The relevant peer-reviewed work on tigilanol tiglate reports differential effects on tumour versus normal cells in pre-clinical models, although the precise thresholds vary by cell type and exposure.

Oral extract versus injectable pharmaceutical — a scope note

All the mechanistic work cited here was conducted with pharmaceutical-grade tigilanol tiglate applied directly to cells or administered by intratumoural injection — the route used for the approved veterinary product. Oral dietary supplements based on whole-seed blushwood berry extract are a different product category, subject to DSHEA and equivalent international frameworks, and are not intended to diagnose, treat, cure, or prevent any disease. The mechanistic literature is cited here for research context only.

Related reading

For adjacent mechanism coverage see our articles on NF-κB signalling in the EBC-46 pathway and the cytolytic cascade of tigilanol tiglate.

Citations

1. Boyle GM et al. — Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models, PLoS ONE, 2014.

2. Barrett RW et al. — Tigilanol tiglate mechanism of action review, Molecules, 2020.

3. Hetz C & Papa FR — The unfolded protein response and cell fate control, Nature Reviews Molecular Cell Biology, 2018.

4. Blushwood Health — dietary supplement background, accessed 2026.